Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Maslowski John Michael

2. Date of Event Requiring Statement (MM/DD/YYYY) 5/14/2014

3. Issuer Name and Ticker or Trading Symbol

Fibrocell Science, Inc. [FCSC]

(Last) (First) (Middle)

405 EAGLEVIEW BOULEVARD

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
V.P., Scientific Affairs /

(Street)

EXTON, PA 19341

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	480	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to Purchase Common Stock	⁽¹⁾	10/6/2019	Common Stock	4000	$18.75	D
Option to Purchase Common Stock	⁽²⁾	1/14/2021	Common Stock	13600	$15.50	D
Option to Purchase Common Stock	⁽³⁾	7/19/2023	Common Stock	17500	$5.49	D
Option to Purchase Common Stock	⁽⁴⁾	1/17/2024	Common Stock	20000	$4.95	D
Option to Purchase Common Stock	⁽⁵⁾	5/13/2024	Common Stock	20000	$2.94	D
Warrant to Purchase Common Stock	1/21/2011	12/31/2016	Common Stock	960	$6.25	D

Explanation of Responses:
( 1)	50% of the Option to Purchase Common Stock vested on October 6, 2010 and 50% of the Option to Purchase Common Stock vested on the date the Issuer received approval for azficel-T.
( 2)	50% of the Option to Purchase Common Stock vested on January 14, 2011, 25% of the Option to Purchase Common Stock vested on January 14, 2012 and 25% of the Option to Purchase Common Stock vested on January 14, 2013.
( 3)	25% of the Option to Purchase Common Stock vested on July 19, 2013, 25% of the Option to Purchase Common Stock will vest on July 19, 2014, 25% of the Option to Purchase Common Stock will vest on July 19, 2015 and 25% of the Option to Purchase Common Stock will vest on July 19, 2016; in each case provided the reporting person is providing services to the Issuer on each vesting date.
( 4)	25% of the Option to Purchase Common Stock will vest on January 17, 2015, 25% of the Option to Purchase Common Stock will vest on January 17, 2016, 25% of the Option to Purchase Common Stock will vest on January 17, 2017, and 25% of the Option to Purchase Common Stock will vest on January 17, 2018; in each case provided the reporting person is providing services to the Issuer on each vesting date.
( 5)	25% of the Option to Purchase Common Stock will vest on May 13, 2015, 25% of the Option to Purchase Common Stock will vest on May 13, 2016, 25% of the Option to Purchase Common Stock will vest on May 13, 2017, and 25% of the Option to Purchase Common Stock will vest on May 13, 2018; in each case provided the reporting person is providing services to the Issuer on each vesting date.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Maslowski John Michael 405 EAGLEVIEW BOULEVARD EXTON, PA 19341			V.P., Scientific Affairs

Signatures
/s/ John Maslowski		5/23/2014
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.